Nanocarriers: more than tour de force for thymoquinone.

Rathore, C; Rathbone, MJ; Chellappan, DK; Tambuwala, MM; Pinto, TDJA; Dureja, H; Hemrajani, C; Gupta, G; Dua, K; Negi, P

Nanocarriers: more than tour de force for thymoquinone.

Rathore, C Rathbone, MJ Chellappan, DK Tambuwala, MM Pinto, TDJA Dureja, H Hemrajani, C Gupta, G Dua, K

Negi, P

Permalink

Publisher:: TAYLOR & FRANCIS LTD
Publication Type:: Journal Article
Citation:: Expert opinion on drug delivery, 2020, 17, (4), pp. 479-494
Issue Date:: 2020-04

Closed Access

	Filename	Description	Size
	Nanocarriers more than tour de force for thymoquinone.pdf	Published version	2.29 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Rathore, C
dc.contributor.author	Rathbone, MJ
dc.contributor.author	Chellappan, DK
dc.contributor.author	Tambuwala, MM
dc.contributor.author	Pinto, TDJA
dc.contributor.author	Dureja, H
dc.contributor.author	Hemrajani, C
dc.contributor.author	Gupta, G
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Negi, P
dc.date.accessioned	2020-08-24T06:21:59Z
dc.date.available	2020-08-24T06:21:59Z
dc.date.issued	2020-04
dc.identifier.citation	Expert opinion on drug delivery, 2020, 17, (4), pp. 479-494
dc.identifier.issn	1742-5247
dc.identifier.issn	1744-7593
dc.identifier.uri	http://hdl.handle.net/10453/142332
dc.description.abstract	Introduction: Thymoquinone (TQ), 2-isopropyl-5-methylbenzo-1, 4-quinone, the main active constituent of Nigella sativa (NS) plant, has been proven to be of great therapeutic aid in various in vitro and in vivo conditions. Despite the promising therapeutic activities of TQ, this molecule is not yet in the clinical trials, restricted by its poor biopharmaceutical properties including photo-instability.Area covered: This review compiles the different types of polymeric and lipidic nanocarriers (NCs), encapsulating TQ for their improved oral bioavailability, and augmented in vitro and in vivo efficacy, evidenced on various pathologies. Furthermore, we provide a comprehensive overview of TQ in relation to its encapsulation approaches advancing the delivery and improving the efficacy of TQ.Expert opinion: TQ was first identified in the essential oil of Nigella sativa L. black seed. TQ has not been used in formulations because it is a highly hydrophobic drug having poor aqueous solubility. To deal with the poor physicochemical problems associated with TQ, various NCs encapsulating TQ have been tried in the past. Nevertheless, these NCs could be impending in bringing forth this potential molecule to clinical reality. This will also be beneficial for a large research community including pharmaceutical & biological sciences and translational researchers.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	TAYLOR & FRANCIS LTD
dc.relation.ispartof	Expert opinion on drug delivery
dc.relation.isbasedon	10.1080/17425247.2020.1730808
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.title	Nanocarriers: more than tour de force for thymoquinone.
dc.type	Journal Article
utslib.citation.volume	17
utslib.location.activity	England
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2020-08-24T06:21:54Z
pubs.issue	4
pubs.publication-status	Published
pubs.volume	17
utslib.citation.issue	4

Abstract:

Introduction: Thymoquinone (TQ), 2-isopropyl-5-methylbenzo-1, 4-quinone, the main active constituent of Nigella sativa (NS) plant, has been proven to be of great therapeutic aid in various in vitro and in vivo conditions. Despite the promising therapeutic activities of TQ, this molecule is not yet in the clinical trials, restricted by its poor biopharmaceutical properties including photo-instability.Area covered: This review compiles the different types of polymeric and lipidic nanocarriers (NCs), encapsulating TQ for their improved oral bioavailability, and augmented in vitro and in vivo efficacy, evidenced on various pathologies. Furthermore, we provide a comprehensive overview of TQ in relation to its encapsulation approaches advancing the delivery and improving the efficacy of TQ.Expert opinion: TQ was first identified in the essential oil of Nigella sativa L. black seed. TQ has not been used in formulations because it is a highly hydrophobic drug having poor aqueous solubility. To deal with the poor physicochemical problems associated with TQ, various NCs encapsulating TQ have been tried in the past. Nevertheless, these NCs could be impending in bringing forth this potential molecule to clinical reality. This will also be beneficial for a large research community including pharmaceutical & biological sciences and translational researchers.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/142332